Clinical Trial Update: Open Label Study to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ™) [Phase 4]

View source ↗

Summary

Open-label Phase 4 study assessing the absolute bioavailability of tasimelteon (HETLIOZ) in adults with non-24-hour sleep-wake disorder; results were posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-24-hour Sleep-wake Disorder

Drugs mentioned

• Hetlioz (tasimelteon)

Snippet

Sponsor: Vanda Pharmaceuticals | Conditions: Non-24-Hour-Sleep-Wake Disorder | Phase 4 | Status: COMPLETED | Results posted: 2016-07-22